A Phase I Study of CLR 131 in Children, Adolescents, and Young Adults with Recurrent or Persistent Solid Tumors, Lymphoma, and Brain Tumors – On…

Full TitleAn Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors (CLOVER-2)Purpose

The purpose of this study is to find the highest dose of the investigational drug CLR 131 that can be given safely in children, adolescents, and young adults with solid tumors, lymphoma, or malignant brain tumors that came back or continued to grow despite treatment. CLR 131 is a targeted form of radiotherapy. It gives off cancer-killing doses of radiation to tumor tissue while limiting the effects of radiation on surrounding normal tissues and organs.

Patients in this study will either receive a single dose of CLR 131 or the same amount divided into two doses given two weeks apart. CLR 131 is given intravenously (by vein).

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.

Read more from the original source:

A Phase I Study of CLR 131 in Children, Adolescents, and Young Adults with Recurrent or Persistent Solid Tumors, Lymphoma, and Brain Tumors - On...